Who we are

CLS is a Swedish high-tech medical device company that has been in operation since 2006 within the dynamic landscape between sophisticated medical technology and advanced medical treatment.

Latest News

    • 15 AUG 16
    • 0

    First patient treated with CLS imILT method at the University Hospital in Verona

    Clinical Laserthermia Systems (CLS) (publ), which develops and markets Interstitial Laser Thermo Therapy (imILTCLS), a polyclinical hyperthermic (heat-induced) cancer immunotherapy for gentle and effective treatment of most types of solid cancer tumors, announces that the first patient has been treated within the clinical study, regarding imILT-treatment of advanced pancreatic cancer, that the Company carries out

    Read more →
    • 09 AUG 16
    • 0

    CLS sponsors Affinity Proteomics 2017

    Clinical Laserthermia Systems (CLS) (publ), will be a sponsor of the Alpbach Affinity Proteomics Workshop in March 2017. The Affinity Proteomics Workshop, being held for the seventh time, is a meeting at which the latest research on antibodies and other protein-binding molecules and their role in cells and tissues are discussed. The meeting will be

    Read more →

What we do


Our mission is to provide products that improve treatment for cancer patients by offering significant and long-lasting health benefits, while reducing cost-of-care for society. The company was founded based on the results of 20 years of intense research within immunotherapy and thermotherapy.

imILTCLS (immunostimulating Interstitial Laser Thermotherapy by CLS) is a new, promising treatment in the growing field of cancer immunotherapy. The minimally invasive, thermal treatment is performed using the TRANBERGCLS | Cancer Immunotherapy System designed to achieve local tumor destruction and specific anti-tumor immunity.